XML 30 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statement of Equity - USD ($)
$ in Millions
Total
The StayWell Company LLC
Vallee S.A.
Common Stock
Other Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Treasury Stock
Non- controlling Interests
Non- controlling Interests
The StayWell Company LLC
Non- controlling Interests
Vallee S.A.
Beginning Balance at Dec. 31, 2015 $ 44,767     $ 1,788 $ 40,222 $ 45,348 $ (4,148) $ (38,534) $ 91    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net Income Attributable to Merck & Co., Inc. 3,920         3,920          
Other comprehensive income (loss), net of taxes (1,078)           (1,078)        
Cash dividends declared on common stock (1.99 per share in 2018, $1.89 per share in 2017 and $1.85 per share in 2016) (5,135)         (5,135)          
Treasury stock shares purchased (3,434)             (3,434)      
Acquisition   $ 124               $ 124  
Net loss attributable to noncontrolling interests 21               21    
Distributions attributable to noncontrolling interests (16)               (16)    
Share-based compensation plans and other 1,139       (283)     1,422      
Ending Balance at Dec. 31, 2016 40,308     1,788 39,939 44,133 (5,226) (40,546) 220    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net Income Attributable to Merck & Co., Inc. 2,394         2,394          
Other comprehensive income (loss), net of taxes 316           316        
Cash dividends declared on common stock (1.99 per share in 2018, $1.89 per share in 2017 and $1.85 per share in 2016) (5,177)         (5,177)          
Treasury stock shares purchased (4,014)             (4,014)      
Acquisition     $ 7               $ 7
Net loss attributable to noncontrolling interests 24               24    
Distributions attributable to noncontrolling interests (18)               (18)    
Share-based compensation plans and other 729       (37)     766      
Ending Balance at Dec. 31, 2017 34,569     1,788 39,902 41,350 (4,910) (43,794) 233    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net Income Attributable to Merck & Co., Inc. 6,220         6,220          
Other comprehensive income (loss), net of taxes (361)           (361)        
Cash dividends declared on common stock (1.99 per share in 2018, $1.89 per share in 2017 and $1.85 per share in 2016) (5,313)         (5,313)          
Treasury stock shares purchased (9,091)       (1,000)     (8,091)      
Net loss attributable to noncontrolling interests (27)               (27)    
Distributions attributable to noncontrolling interests (25)               (25)    
Share-based compensation plans and other 862       (94)     956      
Ending Balance at Dec. 31, 2018 26,882     $ 1,788 $ 38,808 42,579 (5,545) $ (50,929) $ 181    
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Adoption of new accounting standards (see Note 2) $ 48         $ 322 $ (274)